Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 367103, 9 pages
http://dx.doi.org/10.1155/2014/367103
Research Article

Molecular Profiling and Clinical Outcome of High-Grade Serous Ovarian Cancer Presenting with Low- versus High-Volume Ascites

1Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, University of Toronto, Toronto, ON, Canada M5G 2M9
2Department of Obstetrics and Gynaecology, Trillium Health Partners, 2200 Eglinton Avenue West, Mississauga, ON, Canada L5M 2N1
3Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, ON, Canada M5G 2M9
4Department of Laboratory Medicine and Pathology, University Health Network, Toronto, ON, Canada M5T 2M9
5Princess Margaret Genomics Centre, University Health Network, Toronto, ON, Canada M5G 1L7
6Department of Laboratory Medicine and Pathology, Trillium Health Partners, Mississauga, ON, Canada L5M 2N1
7Hospital for Sick Children and Department of Immunology, University of Toronto, Toronto, ON, Canada M5G 1X8
8Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, Princess Margaret Cancer Centre, Toronto, ON, Canada M5G 2M9
9Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada M5T 3L9

Received 10 March 2014; Accepted 5 May 2014; Published 25 May 2014

Academic Editor: X. Li

Copyright © 2014 Tomer Feigenberg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Sankaranarayanan and J. Ferlay, “Worldwide burden of gynaecological cancer: the size of the problem,” Best Practice and Research: Clinical Obstetrics and Gynaecology, vol. 20, no. 2, pp. 207–225, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. M. J. Birrer, “The origin of ovarian cancer—is it getting clearer?” The New England Journal of Medicine, vol. 363, no. 16, pp. 1574–1575, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. A. M. Karst, K. Levanon, and R. Drapkin, “Modeling high-grade serous ovarian carcinogenesis from the fallopian tube,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 18, pp. 7547–7552, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. W. Tothill, A. V. Tinker, J. George et al., “Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome,” Clinical Cancer Research, vol. 14, no. 16, pp. 5198–5208, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. TCGA, “Integrated genomic analyses of ovarian carcinoma,” Nature, vol. 474, no. 7353, pp. 609–615, 2011. View at Publisher · View at Google Scholar
  6. K. Yoshihara, T. Tsunoda, D. Shigemizu et al., “High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway,” Clinical Cancer Research, vol. 18, no. 5, pp. 1374–1385, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Shen-Gunther and R. S. Mannel, “Ascites as a predictor of ovarian malignancy,” Gynecologic Oncology, vol. 87, no. 1, pp. 77–83, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. C. G. Gerestein, M. J. Eijkemans, J. Bakker et al., “Nomogram for suboptimal cytoreduction at primary surgery for advanced sage ovarian cancer,” Anticancer Research, vol. 31, no. 11, pp. 4043–4049, 2011. View at Google Scholar · View at Scopus
  9. M. M. Gilani, M. Karimi Zarchi, F. Ghaemmaghami, N. Behtash, A. S. Mousavi, and S. Ansaripoor, “A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer,” Gynecologic Oncology, vol. 105, no. 3, pp. 780–783, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. E. J. Tanner, K. C. Long, Q. Zhou et al., “Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer,” Gynecologic Oncology, vol. 126, no. 1, pp. 58–63, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. D. S. Chi, J. B. Liao, L. F. Leon et al., “Identification of prognostic factors in advanced epithelial ovarian carcinoma,” Gynecologic Oncology, vol. 82, no. 3, pp. 532–537, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. S. M. Rosenberg, “Palliation of malignant ascites,” Gastroenterology Clinics of North America, vol. 35, no. 1, pp. 189–199, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Becker and H. E. Blum, “VEGF Trap for the treatment of malignant ascites,” The Lancet Oncology, vol. 13, no. 2, pp. 115–116, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Nagy, E. M. Masse, K. T. Herzberg et al., “Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation,” Cancer Research, vol. 55, no. 2, pp. 360–368, 1995. View at Google Scholar · View at Scopus
  15. S. Liao, J. Liu, P. Lin, T. Shi, R. K. Jain, and L. Xu, “TGF-β blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models,” Clinical Cancer Research, vol. 17, no. 6, pp. 1415–1424, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Kipps, D. S. P. Tan, and S. B. Kaye, “Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research,” Nature Reviews Cancer, vol. 13, no. 4, pp. 273–282, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. K. L. Sodek, K. J. Murphy, T. J. Brown, and M. J. Ringuette, “Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis,” Cancer and Metastasis Reviews, vol. 31, no. 1-2, pp. 397–414, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. B. Eisen, P. T. Spellman, P. O. Brown, and D. Botstein, “Cluster analysis and display of genome-wide expression patterns,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 25, pp. 14863–14868, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. G. K. Smyth, “Linear models and empirical bayes methods for assessing differential expression in microarray experiments,” Statistical Applications in Genetics and Molecular Biology, vol. 3, no. 1, article 3, 2004. View at Google Scholar · View at Scopus
  20. A. Subramanian, P. Tamayo, V. K. Mootha et al., “Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 43, pp. 15545–15550, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. R. A. Soslow, G. Han, K. J. Park et al., “Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma,” Modern Pathology, vol. 25, no. 4, pp. 625–636, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Sato, S. H. Olson, J. Ahn et al., “Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 51, pp. 18538–18543, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Leffers, M. J. M. Gooden, R. A. De Jong et al., “Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer,” Cancer Immunology, Immunotherapy, vol. 58, no. 3, pp. 449–459, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. C. C. Preston, E. L. Goode, L. C. Hartmann, K. R. Kalli, and K. L. Knutson, “Immunity and immune suppression in human ovarian cancer,” Immunotherapy, vol. 3, no. 4, pp. 539–556, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Zhang, J. R. Conejo-Garcia, D. Katsaros et al., “Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer,” The New England Journal of Medicine, vol. 348, no. 3, pp. 203–213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Clarke, A. V. Tinker, C.-H. Lee et al., “Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss,” Modern Pathology, vol. 22, no. 3, pp. 393–402, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Callahan, Z. Nagymanyoki, T. Bonome et al., “Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer,” Clinical Cancer Research, vol. 14, no. 23, pp. 7667–7673, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Vitale, G. Pelusi, B. Taroni et al., “HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage,” Clinical Cancer Research, vol. 11, no. 1, pp. 67–72, 2005. View at Google Scholar · View at Scopus
  29. L. Han, M. S. Fletcher, D. L. Urbauer et al., “HLA class i antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma,” Clinical Cancer Research, vol. 14, no. 11, pp. 3372–3379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Vergote, C. G. Tropé, F. Amant et al., “Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer,” The New England Journal of Medicine, vol. 363, no. 10, pp. 943–953, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. W. E. Winter III, G. L. Maxwell, C. Tian et al., “Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 25, no. 24, pp. 3621–3627, 2007. View at Publisher · View at Google Scholar · View at Scopus